Cargando…

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy

BACKGROUND: Pathologic complete response (pCR) is associated with improved survival outcomes in patients with HER2-positive primary breast cancer. We developed a nomogram to predict the probability of pCR rates by using oestrogen receptor (ER) expression, progesterone receptor (PR) expression and HE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujii, Takeo, Kogawa, Takahiro, Wu, Jimin, Sahin, Aysegul A, Liu, Dian D, Chavez-MacGregor, Mariana, Giordano, Sharon H, Raghavendra, Akshara, Murthy, Rushmy K, Tripathy, Debu, Shen, Yu, Yamal, Jose-Miguel, Ueno, Naoto T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318977/ https://www.ncbi.nlm.nih.gov/pubmed/28081544 http://dx.doi.org/10.1038/bjc.2016.444

Ejemplares similares

Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''
por: Fujii, Takeo, et al.
Publicado: (2017)

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
por: Masuda, Hiroko, et al.
Publicado: (2017)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS
por: Trevino, Christopher R, et al.
Publicado: (2019)

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma
por: Mimura, K, et al.
Publicado: (2005)

Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma
por: Maruyama, T, et al.
Publicado: (2010)

Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer
por: Barcenas, Carlos H., et al.
Publicado: (2021)

Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
por: Mouabbi, Jason A., et al.
Publicado: (2022)

ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors
por: Mogol, Ayca, et al.
Publicado: (2022)

Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer
por: Kogawa, Takahiro, et al.
Publicado: (2015)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

Genetic Testing Strategies in Newly Diagnosed Endometrial Cancer Patients Aimed at Reducing Morbidity or Mortality from Lynch Syndrome in the Index Case or Her Relatives
por: Stewart, Alison
Publicado: (2013)

PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas
por: Aubele, M, et al.
Publicado: (2007)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Cheng, et al.
Publicado: (2017)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Tense Bullae and Urticaria in a Woman in Her Sixties
por: Wurlitzer, Katherine C., et al.
Publicado: (2015)

The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer
por: Ning, Jing, et al.
Publicado: (2019)

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer
por: Soysal, S D, et al.
Publicado: (2013)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018)

Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy
por: Yoshikawa, R, et al.
Publicado: (2008)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

Development and validation of nomogram combining serum biomarker for predicting survival in patients with resected rectal cancer
por: Fan, Shaonan, et al.
Publicado: (2019)

The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer
por: Beresford, M J, et al.
Publicado: (2006)

Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment
por: Miller, W R, et al.
Publicado: (2006)

Detection of HER2 amplification in circulating free DNA in patients with breast cancer
por: Page, K, et al.
Publicado: (2011)

Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer
por: Mori, N, et al.
Publicado: (2010)

Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice
por: Murthy, Rashmi K., et al.
Publicado: (2020)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020)

Reassessing Estrogen Receptor Expression Thresholds for Breast Cancer Prognosis in HER2-negative Patients Using Shape Restricted Modeling
por: Dong, Wenli, et al.
Publicado: (2023)

Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy
por: Manton, D J, et al.
Publicado: (2006)

Internal mammary lymph nodal response to neoadjuvant chemotherapy on imaging and breast cancer prognosis
por: Adam, Richard, et al.
Publicado: (2022)

A positive role for PEA3 in HER2-mediated breast tumour progression
por: Myers, E, et al.
Publicado: (2006)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream(®) in patients with breast cancer treated with primary systemic therapy
por: Le Du, Fanny, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7jnavviqjtrio8oudsm51hnvpc